The Intec Pharma Ltd (NASDAQ:NTEC) Given Average Recommendation of “Strong Buy” by Brokerages

The Intec Pharma Ltd (NASDAQ:NTEC) Given Average Recommendation of “Strong Buy” by Brokerages

Intec Pharma Ltd (NASDAQ:NTEC) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a 12-month consensus target price of $9.25 for the company and are forecasting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given Intec Pharma an industry rank of 108 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th.

Several large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC increased its stake in Intec Pharma by 6.5% in the first quarter. Sabby Management LLC now owns 714,062 shares of the company’s stock worth $2,949,000 after buying an additional 43,613 shares during the last quarter. Opaleye Management Inc. increased its position in shares of Intec Pharma by 1.3% in the first quarter. Opaleye Management Inc. now owns 638,000 shares of the company’s stock valued at $2,629,000 after buying an additional 8,000 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Intec Pharma during the second quarter valued at approximately $2,277,000.

Intec Pharma (NASDAQ:NTEC) opened at 5.59 on Thursday. The firm has a 50-day moving average price of $5.96 and a 200-day moving average price of $4.76. Intec Pharma has a 12 month low of $3.03 and a 12 month high of $6.36. The company’s market capitalization is $63.72 million.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Related posts

Leave a Comment